RedHill Biopharma (RDHL) Cash & Equivalents (2022 - 2024)
RedHill Biopharma (RDHL) has disclosed Cash & Equivalents for 3 consecutive years, with $1.9 million as the latest value for Q4 2024.
- Quarterly Cash & Equivalents fell 66.21% to $1.9 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2024, down 66.21% year-over-year, with the annual reading at $1.9 million for FY2024, 66.21% down from the prior year.
- Cash & Equivalents for Q4 2024 was $1.9 million at RedHill Biopharma, down from $5.6 million in the prior quarter.
- The five-year high for Cash & Equivalents was $20.0 million in Q4 2022, with the low at $1.9 million in Q4 2024.
- Average Cash & Equivalents over 3 years is $9.1 million, with a median of $5.6 million recorded in 2023.
- The sharpest move saw Cash & Equivalents tumbled 72.11% in 2023, then tumbled 66.21% in 2024.
- Over 3 years, Cash & Equivalents stood at $20.0 million in 2022, then crashed by 72.11% to $5.6 million in 2023, then crashed by 66.21% to $1.9 million in 2024.
- According to Business Quant data, Cash & Equivalents over the past three periods came in at $1.9 million, $5.6 million, and $20.0 million for Q4 2024, Q4 2023, and Q4 2022 respectively.